The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine

NCT07131826 | Not Yet Recruiting

• 1 other identifier: 202503037RINA
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

"AIDS" was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.

Conditions

Viral Control; Quality of Life; Cabotegravir; Rilpivirine; AIDS

Keywords

cabotegravir; rilpivirine; AIDS; quality of life; viral control

Outcome Measures

Primary Outcomes (1)

• To whether long-acting injections can significantly improve the quality of daily life of people infected with HIV using a questionnaire

  From the date of approval by the CTC to December 31, 2026.

Study Arms (1)

AIDS patients after long-acting injection of cabotegravir and rilpivirine

AIDS patients after long-acting injection of cabotegravir and rilpivirine

Other: Observational study, non-interventional

Interventions

Observational study, non-interventional OTHER

Observational study, non-interventional

AIDS patients after long-acting injection of cabotegravir and rilpivirine

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Males or females aged 18 years or older who have completed long-acting injectable treatment for HIV infection.

You may qualify if:

• years and above Clinical diagnosis of HIV infection completed long-acting injectable treatment Accept the questionnaire

You may not qualify if:

• Not clinical diagnosis of HIV infection Do not accept questionnaires

Sponsors & Collaborators

• National Taiwan University Clinical Trial Center: lead
• National Taiwan University Hospital: collaborator

Study Sites (1)

NTUH

Taipei, Taiwan

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Interventions

Observation

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Central Study Contacts

WANG-HUEI SHENG

CONTACT

+886-02-2312-3456; ntuhrec@ntuh.gov.tw

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: WANG-HUEI SHENG professor

Study Record Dates

• First Submitted: April 28, 2025
• First Posted: August 20, 2025
• Study Start: August 15, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: August 20, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL

Locations

TW (1)